Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study

Brain

Volumn 122, Issue 2, 1999, Pages 191-197

  Lee, M A ^a   Palace, J ^a   Stabler, G ^b   Ford, J ^b   Gearing, A ^b   Miller, K ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Matrix metalloproteinases; Multiple sclerosis; TIMP and MRI

Indexed keywords

GADOLINIUM; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENCEPHALITIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; ALZHEIMER DISEASE; COLLAGENASES; CROSS-SECTIONAL STUDIES; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MENINGITIS, BACTERIAL; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0032948343     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.2.191     Document Type: Article

References (25)

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23: 406-15.
2. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990; 50: 2322-9.
3. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. [Review]. Neurosci Biobehav Rev 1996; 20: 445-52.
4. Banik NL. Pathogenesis of myelin breakdown in demyelinating diseases: role of proteolytic enzymes. [Review]. Crit Rev Neurobiol 1992; 6: 257-71.
5. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. [Review]. J Neuroimmunol 1997; 72: 155-61.
6. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997; 74: 85-94.
7. Colton CA, Keri JE, Chen WT, Monsky WL. Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res 1993; 35: 297-304.
8. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
9. Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, et al. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. [Review]. Int J Obes Relat Metab Disord 1996; 20 Suppl 3: S9-15.
10. Feuerstein GZ, Liu T and Barone FC. Cytokines, inflammation and brain injury: role of tumor necrosis factor-alpha. [Review]. Cerebrovasc Brain Metab Rev 1994; 6: 341-60.
11. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-7.
12. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
13. Goetzl EJ, Banda MJ and Leppert D. Matrix metalloproteinases in immunity. [Review]. J Immunol 1996; 156: 1-4.
14. Hermans G, Stinissen P, Hauben L, Van den Berg Loonen E, Raus J. Zhang J. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 1997; 42: 18-27.
15. Kleiner DE, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993; 5: 891-7.
16. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
17. Miller KM, Ford JC, Ward GA, Palace J. Increase in 92kDa gelatinase in serum is associated with clinical relapse in patients with multiple sclerosis [abstract]. J Neurol Neurosurg Psychiatry 1996; 61: 225-6.
18. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the 'hemopexin' domain? [Review]. Matrix Biol 1997; 15: 511-8.
19. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. [Review]. J Neurosci Res 1996; 45: 322-33.
20. Paemen L, Olsson T, Soderstrom M, Van Damme J, Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994; 1: 55-63.
21. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192: 1175-81.
22. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of the blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-7.
23. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995; 703: 151-5.
24. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-32.
25. Sobel RA. The pathology of multiple sclerosis. [Review]. Neurol Clin 1995; 13: 1-21.